Evaluation Of Clinical Effect Of Nicorandil On Patients After PCI Based On Cardiopulmonary Exercise Test

ObjectiveTo investigate the clinical efficacy of Nicorandil in improving exercise tolerance in patients after percutaneous coronary intervention(PCI),and to evaluate its safety,providing reference for further improvement of quality of life and prognosis in patients after PCI.MethodsThis study is a retrospective study.Patients who underwent percutaneous coronary intervention(PCI)and met the diagnostic and inclusion/exclusion criteria were selected from the Department of Cardiology at the Third Affiliated Hospital of Guangzhou Medical University between June 2020 and November 2022.The patients were divided into an experimental group(treated with Nicorandil in combination with conventional treatment for coronary heart disease)consisting of 88 cases and a control group(treated only with conventional treatment for coronary heart disease)consisting of 156 cases.After propensity score matching,50 pairs of data(50 cases in the experimental group and 50 cases in the control group)were obtained.Biochemical results including CRP,blood glucose,liver and kidney function,myocardial enzymes,as well as relevant data from cardiopulmonary exercise testing were collected at baseline and 12 weeks after treatment for the matched groups.The improvement of exercise tolerance and major indicators such as CRP,blood glucose,liver and kidney function,and myocardial enzymes were analyzed and compared between the matched groups to evaluate the clinical efficacy of Nicorandil in treating patients after PCI.Results1.Comparison of cardiopulmonary exercise testing indicators between the two groups of patients: The improvement in peak oxygen uptake(Peak VO2)and total exercise time in the experimental group was significantly better than that in the control group,with a statistically significant difference(p<0.05).However,the difference in improvement in metabolic equivalents between the two groups was not statistically significant(p>0.05).2.Comparison of biochemical test indicators between the two groups of patients: The improvement in renal function and serum CRP level in the experimental group was significantly better than that in the control group,with a statistically significant difference(p<0.05).However,the difference in improvement in blood glucose,liver function(ALT,AST),renal function(SCr),and myocardial enzymes(CK,CK-MB)was not statistically significant(p>0.05)between the two groups.Conclusion1.PCI postoperative patients who receive nicorandil in addition to traditional coronary heart disease treatment for three months can increase their peak oxygen uptake,prolong total exercise time,and significantly improve exercise tolerance.2.Nicorandil can improve renal function and reduce serum CRP levels in patients after PCI.